

The Medical Letter[®]

on Drugs and Therapeutics

Volume 65

Published online August 21, 2023

Online
Article

IN THIS ISSUE

In Brief: A New Endometrial Cancer Indication for Dostarlimab (*Jemperli*)

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 65

Published online August 21, 2023

Online
Article

IN THIS ISSUE

In Brief: A New Endometrial Cancer Indication for Dostarlimab (*Jemperli*)

IN BRIEF

A New Endometrial Cancer Indication for Dostarlimab (*Jemperli*)

The immune checkpoint inhibitor dostarlimab-gxly (*Jemperli* – GSK) has been approved by the FDA for use in combination with carboplatin and paclitaxel for treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Dostarlimab was recently granted regular approval for treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed on or following a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.¹

MECHANISM OF ACTION – Binding of PD-L1 and PD-L2 to programmed death receptor-1 (PD-1) on T cells suppresses T-cell proliferation and cytokine production. Dostarlimab binds to PD-1 on T cells, blocking its interaction with PD-L1 and PD-L2 and restoring T-cell antitumor immune responses. dMMR tumors are more responsive to PD-1 blockade than mismatch repair-proficient tumors.

CLINICAL STUDIES – FDA approval of the new indication was based on the results of a double-blind trial (RUBY) in 494 patients with primary advanced (stage III or IV) endometrial cancer or a first recurrence of endometrial cancer. Patients were randomized to receive dostarlimab or placebo in addition to carboplatin and paclitaxel every 3 weeks for 6 cycles, followed by dostarlimab or placebo alone every 6 weeks for up to 3 years. In the 118 patients with dMMR/MSI-H tumors, estimated progression free survival (PFS) at 24 months was 61.4% in the dostarlimab arm and 15.7% in the placebo arm, a statistically significant difference. In the overall population, estimated PFS at 24 months was also

statistically significantly higher in the dostarlimab arm compared to the placebo arm (36.1% vs 18.1%). Overall survival at 24 months was 71.3% with dostarlimab and 56.0% with placebo.²

ADVERSE EFFECTS – Infusion-related reactions and severe immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, and skin reactions, can occur with use of dostarlimab. Serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after a PD-1/PDL1 blocking antibody. Liver enzymes, creatinine, and thyroid function should be assessed before starting and periodically during treatment. The drug should be discontinued in patients who experience grade 4 immune-mediated adverse reactions.

DOSAGE, ADMINISTRATION, AND COST – The recommended dosage of dostarlimab for the new indication is 500 mg administered IV over 30 minutes every 3 weeks for 6 doses with carboplatin and paclitaxel, followed by 1000 mg every 6 weeks until disease progression or unacceptable toxicity occurs or up to 3 years. Dostarlimab should be given before chemotherapy if they are both given on the same day. The label includes dosage modifications that should be made if adverse effects occur. The wholesale acquisition cost of one 1000-mg dose of *Jemperli* is \$21,900.³ ■

1. Dostarlimab (*Jemperli*) for endometrial cancer. *Med Lett Drugs Ther* 2023; 65:e64.
2. MR Mirza et al. Dostarlimab for primary advanced or recurrent endometrial cancer. *N Engl J Med* 2023; 388:2145.
3. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. August 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/policies/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:



Copyright 2023. ISSN 1523-2859

